Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2008

Rentschler and Boehringer Ingelheim Offer Combined Production Services

  • Rentschler Biotechnologie and Boehringer Ingelheim inked a preferred partnership agreement that allows their respective clients to use the other’s facilities. Rentschler’s clients will have access to Boehringer Ingelheim’s large-scale mammalian biopharmaceutical production plants in Biberach, Germany. Also, Boehringer Ingelheim’s clients will be able to use Rentschler’s facilities for process development and intermediate-scale clinical supply production.

    The firms believe that companies will benefit from the combined development and manufacturing know-how and facilities, leading to increased flexibility and ultimately more customized services.

    Rentschler Biotechnologie is a CMO focused on process development and small-to-medium scale production of mammalian cell-derived biopharmaceuticals. The company currently operates eight independent GMP lines with fermentor volumes of up to 500 L. A 2,500 L fermentor was recently qualified as well, according to the firm.

    Boehringer Ingelheim offers similar services with technologies optimized for large-scale industrial production. The company runs one of the largest biotech facilities with fermenter volumes of up to 15,000 L.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »